Amgen
AMGN · NASDAQ
Bulios Fair Price
$488.35
27.7% upside
Current Price
$382.47
According to Bulios Fair Price, AMGN is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Amgen Inc. is an American biotechnology company specializing in research, development, and manufacturing of biologic medicines. The company focuses on innovative therapeutic treatments for various diseases, including cancer, cardiovascular conditions, arthritis, and other serious illnesses. Amgen has developed a range of successful drugs that have transformed the lives of patients worldwide. The company also invests in research for new drugs and treatment approaches to better address current and future healthcare challenges. Amgen collaborates with physicians, scientists, and other experts to improve healthcare and develop new therapeutic options. Amgen Inc. (AMGN) shares are an interesting choice for investors who follow the biotechnology sector and seek investment opportunities in a reputable company that brings innovative therapeutic treatments for serious diseases.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert A. Bradway
Employees
31,500
Headquarters
Thousand Oaks
Upcoming events
Earnings
Upcoming earnings report